Safety and tolerability of sorafenib for treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC): Detailed analyses from the phase III DECISION trial

Authors

Publication/Presentation Date

5-2014

Volume

32

Issue

15

Disciplines

Medicine and Health Sciences

Department(s)

Hematology-Medical Oncology Division

Document Type

Article

Share

COinS